Perrigo PRGO
Perrigo FY 2025: revenue $4.3B, down 3%; diluted EPS −$10.29
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001585364-26-000009
Key figures from this report
These are the numbers Perrigo reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$4.3B−3% from $4.4B in FY 202410-K income statement, on EDGAR
- Net income−$1.4BAgainst −$171.8M in FY 202410-K income statement, on EDGAR
- Diluted EPS−$10.29Against −$1.25 in FY 202410-K income statement, on EDGAR
- Cash and cash equivalents$531.6M−5% from $558.8M in FY 202410-K balance sheet, on EDGAR
- Cash from operations$238.5M−34% from $362.9M in FY 202410-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Vaxcyte PCVX public float $3.7B, Jun 30, 2025
- Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
- Ultragenyx Pharmaceutical RARE public float $3.4B, Jun 30, 2025
- Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
- Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
